AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler ... looking for medicines that could reduce likelihood of expensive emergency hospital visits due to COPD.

Triple therapy of an inhaled corticosteroid, long acting β 2-agonist (LABA), and long acting muscarinic antagonist (LAMA) is more effective in reducing the annual rate of exacerbations compared with ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

In patients with chronic obstructive pulmonary disease (COPD), the first year of using single-inhaler triple therapy is associated with slightly more major adverse cardiovascular events (MACE) than ...

GlaxoSmithKline won approval for a three-drug COPD inhaler, Trelegy Ellipta, in 2017. 3D medical animation services have emerged as a groundbreaking tool in the healthcare industry ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14) compared ...

Do not initiate in rapidly deteriorating or potentially life-threatening episodes of COPD ... of inhaled sympathomimetic drugs. Patients using Trelegy Ellipta should not use another medicine ...

Metered-dose inhaler budesonide ... or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14) compared with the dry-powder competitor fluticasone-umeclidinium-vilanterol (Trelegy Ellipta) over ...

In this retrospective cohort study, Trishul Siddharthan, MD, associate professor of medicine at University of Miami, and colleagues evaluated 191,823 adults with COPD starting a new inhaled ...

Novartis and Qualcomm are to develop a 'smart' COPD inhaler to allow patients to digitally monitor their medication. The announcement follows similar plans by Novartis's rivals in the respiratory ...

Study: Prevalence of Critical Errors and Insufficient Peak Inspiratory Flow in Patients Hospitalized With COPD in a ...